High intensity focused ultrasound (HIFU) for prostate cancer: current clinical status, outcomes and future perspectives

Int J Hyperthermia. 2010;26(8):796-803. doi: 10.3109/02656736.2010.498803. Epub 2010 Sep 30.

Abstract

Two devices are currently available for the treatment of prostate cancer with HIFU: Sonablate® and Ablatherm®. The outcomes achieved for primary-care patient are very promissing with mid- and long-term progression-free survival rates around 70%, negative postoperative prostate biopsies almost 85%, and an excellent morbidity profile. Moreover, HIFU has a considerable potential for local recurrence after radiation failure. Recently, some early experiences on focal therapy suggest that HIFU could be an excellent option for highly selected patient.

MeSH terms

  • Disease-Free Survival
  • Humans
  • Male
  • Neoplasm Recurrence, Local / therapy
  • Patient Selection
  • Prostatic Neoplasms* / diagnostic imaging
  • Prostatic Neoplasms* / therapy
  • Salvage Therapy
  • Treatment Outcome
  • Ultrasonography
  • Ultrasound, High-Intensity Focused, Transrectal* / instrumentation
  • Ultrasound, High-Intensity Focused, Transrectal* / statistics & numerical data
  • Ultrasound, High-Intensity Focused, Transrectal* / trends